Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy

BACKGROUND: Molecularly targeted therapy has revolutionized the treatment of advanced melanoma. However, despite its high efficiency, a majority of patients experience relapse within 1 year of treatment because of acquired resistance, and approximately 10–25% patients gain no benefit from these agen...

Descripción completa

Detalles Bibliográficos
Autores principales: Olbryt, Magdalena, Pigłowski, Wojciech, Rajczykowski, Marcin, Pfeifer, Aleksandra, Student, Sebastian, Fiszer-Kierzkowska, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028806/
https://www.ncbi.nlm.nih.gov/pubmed/31980996
http://dx.doi.org/10.1007/s11523-020-00695-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028806/
https://www.ncbi.nlm.nih.gov/pubmed/31980996
http://dx.doi.org/10.1007/s11523-020-00695-0

Ejemplares similares